May 31, 2026 at 8:00 a.m. EDT
A breakthrough in pancreatic cancer treatment has emerged with the results of a clinical trial for an experimental pill named daraxonrasib. This development represents a significant stride in combating one of the deadliest forms of cancer.
An illustration of a cancer cell accompanies this report, highlighting the significance of this scientific achievement. Daraxonrasib has not only extended the lives of patients with pancreatic cancer but also maintained control over tumor growth for twice the duration achieved by conventional chemotherapy.
This advance is particularly notable given the drug’s development span of over four decades. The promising results offer new hope to doctors and patients facing this challenging diagnosis.
Increased Funding Needed for Psychiatric Hospitals 
Trump Administration Distributes ACA Refund Checks 
Higher Consumption of Ultra-Processed Foods Linked to Increased Health Risks 
Understanding Inflammation: Myths and Facts 
Calm Parenting: Strategies to Manage Stress 
Trump’s Executive Order to Combat Mosquitoes and Ticks in D.C.